POLB Stock Overview
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Poolbeg Pharma PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.10 |
| 52 Week High | UK£0.12 |
| 52 Week Low | UK£0.064 |
| Beta | 2.26 |
| 1 Month Change | 2.58% |
| 3 Month Change | 15.70% |
| 1 Year Change | 28.39% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.44% |
Recent News & Updates
Recent updates
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Feb 16
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Oct 05We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Jun 01Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation
Jul 12Shareholder Returns
| POLB | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 1.0% | 0.2% | -1.4% |
| 1Y | 28.4% | -5.3% | -2.4% |
Return vs Industry: POLB exceeded the UK Pharmaceuticals industry which returned -3.7% over the past year.
Return vs Market: POLB exceeded the UK Market which returned -1% over the past year.
Price Volatility
| POLB volatility | |
|---|---|
| POLB Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 8.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: POLB has not had significant price volatility in the past 3 months.
Volatility Over Time: POLB's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 12 | Jeremy Skillington | www.poolbegpharma.com |
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.
Poolbeg Pharma PLC Fundamentals Summary
| POLB fundamental statistics | |
|---|---|
| Market cap | UK£49.75m |
| Earnings (TTM) | -UK£4.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.2x
P/E RatioIs POLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POLB income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£4.89m |
| Earnings | -UK£4.89m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0098 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did POLB perform over the long term?
See historical performance and comparison